OptimizeRx Co. (NASDAQ:OPRX) Receives $15.86 Consensus PT from Brokerages

Shares of OptimizeRx Co. (NASDAQ:OPRX) have been given a consensus rating of “Moderate Buy” by the seven analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $15.86.

A number of equities analysts have issued reports on the stock. JMP Securities reissued a “market outperform” rating and set a $15.00 price target on shares of OptimizeRx in a research report on Tuesday, April 16th. Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price target on shares of OptimizeRx in a research report on Monday, April 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price target on shares of OptimizeRx in a report on Monday, April 1st.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Kennedy Capital Management LLC acquired a new stake in shares of OptimizeRx during the third quarter worth about $4,323,000. AWM Investment Company Inc. grew its position in shares of OptimizeRx by 75.8% during the third quarter. AWM Investment Company Inc. now owns 782,571 shares of the company’s stock worth $6,088,000 after buying an additional 337,303 shares in the last quarter. Millrace Asset Group Inc. purchased a new stake in shares of OptimizeRx during the fourth quarter worth approximately $1,917,000. G2 Investment Partners Management LLC lifted its stake in OptimizeRx by 26.0% in the fourth quarter. G2 Investment Partners Management LLC now owns 468,120 shares of the company’s stock worth $6,699,000 after acquiring an additional 96,646 shares during the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in shares of OptimizeRx during the first quarter worth about $1,053,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Trading Up 2.9 %

Shares of NASDAQ:OPRX opened at $10.91 on Tuesday. OptimizeRx has a 1 year low of $6.92 and a 1 year high of $16.65. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.04 and a quick ratio of 3.04. The firm has a market capitalization of $198.39 million, a P/E ratio of -10.80 and a beta of 1.05. The business’s 50-day moving average is $11.73 and its 200 day moving average is $12.18.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $0.11 earnings per share for the quarter. The firm had revenue of $28.37 million for the quarter. OptimizeRx had a negative net margin of 24.56% and a negative return on equity of 7.72%. On average, research analysts predict that OptimizeRx will post -0.49 earnings per share for the current fiscal year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.